The Trispecific Antibody SAR’257 Discontinued After Phase 1 Findings

At ASH 2024, Fredrik Schjesvold presented the results of a phase 1 study on SAR’257, a trispecific antibody drug for treating relapsed refractory myeloma and non-Hodgkin’s lymphoma. Despite its innovative approach of targeting two T-cell receptors (CD3 and CD28), the drug showed high toxicity and low efficacy, leading to its development being discontinued. The study provided valuable insights into T-cell stimulation limits in immunotherapy.